Form 4: CalciMedica Executive Acquires Stock Options
SEC Form 4 Filing
Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.
Summary
- Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., filed a Form 4 on April 25, 2025.
- The report details the acquisition of employee stock options.
- Stauderman acquired options to purchase 125,000 shares of common stock at an exercise price of $1.53 per share on April 23, 2025.
- The options vest in equal monthly installments over a four-year period, beginning March 26, 2025, and expire on April 22, 2035.
- Following the transaction, Stauderman directly owns options for 125,000 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment. This is a routine disclosure of stock option acquisition. It doesn't inherently indicate positive or negative sentiment, but rather provides information about executive compensation.
Positives
- The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This allows investors to monitor the buying and selling activity of executives and directors, which can provide insights into their perspectives on the company's prospects.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
- The vesting schedule of four years with monthly installments is a typical arrangement.
- Comparing the size of the grant to those of executives at comparable companies (e.g., similar market capitalization, stage of development) would provide further context.
Stakeholder Impact
- Shareholders may view this as a positive sign if they believe it aligns management's interests with the company's success.
- Employees may see this as a standard part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 04/23/2025 | Date of transaction: acquisition of employee stock options. |
| 03/26/2025 | Vesting start date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period. |
| 04/22/2035 | Expiration date of the stock options. |
| 04/25/2025 | Date of Form 4 filing. |
Keywords
Form 4, CalciMedica, Stock Options, Beneficial Ownership, Stauderman, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.